Status:
COMPLETED
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Lead Sponsor:
Centre Hospitalier Intercommunal Creteil
Conditions:
Malignant Pleural Mesothelioma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received Programmed cell death 1 (anti-PD1) / (PDL1) Programmed d...
Detailed Description
Immunotherapy is now an option in the treatment of malignant pleural mesothelioma. A French study, Mesothelioma Avastin plus Pemetrexed-cisplatin Study 2 (MAPS 2), prospective in 2nd line or more, fou...
Eligibility Criteria
Inclusion
- Patient over 18 years of age,
- Diagnosis of malignant pleural mesothelioma affirmed by the anatomo-pathological analysis report of a histological sample of the tumour (re-read by MESOPATH).
- Patient who has received at least one injection of anti-PD1 or anti-PDL1 antibodies
Exclusion
- Explicit refusal by the patient to collect data
Key Trial Info
Start Date :
November 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 11 2021
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04775446
Start Date
November 26 2020
End Date
October 11 2021
Last Update
February 4 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Côte basque
Bayonne, France
2
CHU Brest
Brest, France
3
CH Cherbourg
Cherbourg, France
4
CHI Créteil
Créteil, France